Leiden University Medical Center (LUMC)

LUMC is a modern university medical center for research, education and patient care with a high quality profile and a strong scientific orientation. Its unique research practice, ranging from pure fundamental medical research to applied clinical research, places LUMC among the world top. Researchers at LUMC work together around 7 medical research profiles (MRP): Vascular and Regenerative Medicine; Immunity, Infection and Tolerance; Translational Neuroscience; Cancer Pathogenesis and Therapy; Ageing; Innovation in Health Strategy and Quality of Care; and Biomedical Imaging.

The research laboratories of the LUMC are housed on campus and have world-class expertise in Human genetics, Systems Biology and Stem cell and developmental Biology. The intellectual environment within the LUMC is nurtured by presence of world-class research groups in the fields of stem cell biology, developmental biology, genetics, cancer biology, signal transduction and RNA biology. The Institute houses facilities for proteomics, single cell transcriptome and epigenome analysis, confocal imaging, high-volume cell culture, high-throughput imaging-based functional screens, and generation and analysis of transgenic mice.

The LUMC department of Anatomy and Embryology has a strong history in Anatomy education as well as world-class fundamental research into the cellular processes that underlie normal and pathogenic development, tissue homeostasis and regeneration. We work to develop new insights and methods aiming to restore the function of tissues that have been damaged or lost due to disease, trauma or ageing.

Niels Geijsen is Developmental Biology and Regenerative Medicine at Leiden University and head of the Department of Anatomy and Embryology at the LUMC. His team has developed pluripotent stem cell based in vitro research models to study genetic disorders, in particular for genetic muscle diseases such as Duchenne muscular dystrophy and Facio Scapulo Humeral dystrophy (FSHD). In addition, his research group developed a unique new technology that makes it possible to introduce recombinant proteins, including CRISPR/Cas gene-editing complexes into cells.